@article {Khamis:2019:2637-8329:344,
title = "The Added Value of 18F-FDOPA PET/CT in the Work-Up of Patients with Movement Disorders",
journal = "Neurographics",
parent_itemid = "infobike://asnr/ng",
publishercode ="asnr",
year = "2019",
volume = "9",
number = "5",
publication date ="2019-10-01T00:00:00",
pages = "344-348",
itemtype = "ARTICLE",
issn = "2637-8329",
eissn = "2637-8329",
url = "https://asnr.publisher.ingentaconnect.com/content/asnr/ng/2019/00000009/00000005/art00005",
doi = "doi:10.3174/ng.1900004",
keyword = "PD = Parkinson disease, DLB = Lewy body dementia, 18F-FDOPA = 18F-Fluor-l-dopa, DIP = drug-induced parkinsonism, AD = Alzheimer disease",
author = "Khamis, K. and Giladi, N. and Levine, C. and Kesler, M. and Kuten, J. and Lerman, H. and Even-Sapir, E.",
abstract = "Movement disorders represent a common clinical feature in many different neurologic diseases. However, although the clinical features are often similar, there are many different possible etiologies of these movement disorders, which represent a valid diagnostic challenge. Management
of these patients is dependent on an accurate diagnosis of the underlying etiology because the clinical course and treatment may vary significantly. 18F-Fluor-l-dopa has been used as a positron-emitting compound for PET evaluation of patients with movement disorders and parkinsonism.
To emphasize the diagnostic value of combining both morphologic and functional imaging in 18F-Fluor-l-dopa PET/CT, we describe the clinical history and 18F-Fluor-l-dopa PET/CT imaging findings of 5 patients in whom the cause of movement impairment was unclear.",
}